Evaluation of a new heterogeneous immunoassay for the whole-blood determination of cyclosporin on the dade Behring dimension RXL clinical chemistry analyzer;Évaluation du réactif immunologique hété rogène (ACMIA) pour le dosage sanguin de ciclosporine sur RXL HM Dimension®

Annales de Biologie Clinique

Volumn 61, Issue 6, 2003, Pages 713-718

  Morand, K ^a   Huet, E ^a   Blanchet, B ^a   Astier, A ^a   Hulin, A ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

Cyclosporin monitoring; Heterogeneous immunoassay; Immunosuppressive drug; RXL HM Dimension

Indexed keywords

CYCLOSPORIN;

ARTICLE; BLOOD; EVALUATION; HUMAN; IMMUNOASSAY; METHODOLOGY;

CYCLOSPORINE; HUMANS; IMMUNOASSAY;

EID: 1542609839     PISSN: 00033898     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Kahan BD, Welsh M, Rutzky LP. Challenges in cyclosporine therapy: the role of therapeutic monitoring by area under the curve monitoring. Ther Drug Monit 1995 ; 17 : 621-4.
2. Dumont RJ, Ensom MHH. Methods for clinical monitoring of cyclosporin in transplant patients. Clin Pharmacokinet 2000 ; 38 ; 427-47.
3. Grevel J, Welsh M, Kahan BD. Cyclosporine monitoring in renal transplantation: area under the curve monitoring is superior to trough-level monitoring. Ther Drug Monit 1989 ; 11 : 246-8.
4. Grevel J, Kahan BD. Area under the curve monitoring of cyclosporine therapy: the early posttransplant period. Ther Drug Monit 1991 ; 13 : 89-95.
5. Hamwi A, Veitl M, Manner G, Ruzicka K, Schweiger C, Szekeres T. Evaluation of four automated methods for determination of whole blood cyclosporine concentrations. Am J Clin Pathol 1999 ; 112 : 358-65.
6. Holt DW, Johnston A, Kahan BD, Morris RG, Oellerich M, Shaw LM. New approaches to cyclosporine monitoring raise further concerns about analytical techniques. Clin Chem 2000 ; 46 : 872-4.
7. Gulbis B, Van der Heijden J, Van As H, Thiry P. Whole blood cyclosporin monitoring in liver and heart transplant patients: evaluation of the specificity of a fluorescence polarization immunoassay and an enzyme-multiplied immunoassay technique. J Pharm Biomed Anal 1997 ; 15 : 957-63.
8. Vassault A. Procédure de validation d'une technique. Spectra Biologie 1997 ; 16 : 43-50.
9. Hamwi A, Salomon A, Steinbrugger R, Fritzer-Szekeres M, Jager W, Szekeres T. Cyclosporine metabolism in patients after kidney, bone marrow, heart-lung, and liver transplantation in the early and late posttransplant periods. Am J Clin Pathol 2000 ; 114 : 536-43.
10. Yatscoff RW, Aspeslet LJ, Gallant HL. Pharmacodynamic monitoring of immunosuppressive drugs. Clin Chem 1998 ; 44 : 428-32.
11. Terrell AR, Daly TM, Hock KG, et al. Evaluation of a no-pretreatment cyclosporin A assay on the Dade Behring dimension RxL clinchemistry analyzer. Clin Chem 2002 ; 48 : 1059-65.